Holen Sie sich die Stockscreener-App
14.17
24.71%
-4.668
Schlusskurs vom Vortag:
$18.84
Offen:
$18.5
24-Stunden-Volumen:
12.41M
Relative Volume:
6.76
Marktkapitalisierung:
$1.44B
Einnahmen:
$70.85M
Nettoeinkommen (Verlust:
$-324.22M
KGV:
-3.7231
EPS:
-3.8065
Netto-Cashflow:
$-277.36M
1W Leistung:
-23.45%
1M Leistung:
-49.95%
6M Leistung:
-31.90%
1J Leistung:
+18.31%
1-Tages-Spanne:
$13.62
$18.50
1-Wochen-Bereich:
$13.62
$19.84
52-Wochen-Spanne:
$9.90
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
14.12 | 1.93B | 70.85M | -324.22M | -277.36M | -3.8065 |
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Bestätigt | Wedbush | Outperform |
| 2025-12-03 | Eingeleitet | William Blair | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Why Is Viridian Therapeutics Stock Sinking Monday? - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history - Yahoo Finance Singapore
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics (VRDN) slides 26.8% as investors digest Phase 3 REVEAL-1 data and reset expectations - Quiver Quantitative
Viridian Therapeutics (VRDN) Shares Drop Amid Competitor's Trial Success - gurufocus.com
Institution Moves: Is Viridian Therapeutics Inc subject to activist investor interestWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Earnings Report: Should I hold or sell Viridian Therapeutics Inc nowForecast Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $48 - Moomoo
VRDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EBIT per share of Viridian Therapeutics, Inc. – LSE:0K1R - TradingView
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart DataWhat's Changed - Sahm
Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal? - Stocktwits
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-04-02 - Seeking Alpha
Transcript : Viridian Therapeutics, Inc.Special Call - marketscreener.com
Are Viridian Therapeutics' (VRDN) REVEAL-1 Results Enough To Redefine Its TED Competitive Position? - Yahoo Finance
Viridian Therapeutics (VRDN) Target Price Lowered by Evercore IS - gurufocus.com
What is HC Wainwright's Estimate for VRDN FY2027 Earnings? - MarketBeat
Discipline and Rules-Based Execution in VRDN Response - Stock Traders Daily
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock? - qz.com
J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics (VRDN) Jumps 5.6%: Does the Stock Have More Room to Grow? - Bitget
Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly - Seeking Alpha
HC Wainwright Has Negative Outlook for VRDN Q1 Earnings - MarketBeat
Viridian Therapeutics, Inc. $VRDN Stock Position Decreased by JPMorgan Chase & Co. - MarketBeat
Aug Decliners: Will Viridian Therapeutics Inc benefit from geopolitical trends2026 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
Viridian releases phase 3 topline data on elegrobart for TED - Eyes On Eyecare
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $36.00 at The Goldman Sachs Group - MarketBeat
Viridian Therapeutics (VRDN) Analyst Ratings Update: Wells Fargo Lowers Price Target | VRDN Stock News - gurufocus.com
VRDN: Wedbush Lowers Price Target While Maintaining Outperform R - gurufocus.com
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - globenewswire.com
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $20.00 at Wells Fargo & Company - MarketBeat
Viridian shares plummet on elegrobart trial results - The Pharma Letter
VRDN: Analyst Maintains 'Buy' Rating, Lowers Price Target to $22 - gurufocus.com
HC Wainwright Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $22.00 - MarketBeat
H.C. Wainwright cuts Viridian Therapeutic price target on TED trial results - Investing.com Canada
Wolfe Research cuts Viridian Therapeutic price target on trial outlook - Investing.com
Wolfe Research cuts Viridian Therapeutic price target on trial outlook By Investing.com - Investing.com Canada
Viridian reports positive phase 3 trial results for TED drug By Investing.com - Investing.com Australia
Trade Recap: Can Viridian Therapeutics Inc be the next market leaderBuy Signal & Reliable Breakout Forecasts - baoquankhu1.vn
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease - BioSpace
Viridian Therapeutics price target lowered to $32 from $42 at Needham - TipRanks
Published on: 2026-03-31 08:41:04 - baoquankhu1.vn
Viridian Therapeutics price target lowered to $37 from $44 at Wedbush - TipRanks
Viridian Therapeutics (VRDN) Reports Success in Phase 3 Trial fo - gurufocus.com
Viridian Therapeutics Plummets 32% on Mixed Trial Results Despite Record Trading Volume - Bitget
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):